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Abstract 
Review on acute lymphoblastic leukemia in Down 
syndrome, with data on clinics, pathology, and 
involved genes. 
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Clinics and pathology 
Disease 
Acute lymphoblastic leukemia (ALL) associated 
with Down syndrome (ALL-DS), is predominantly a 
B lymphoblastic leukemia, with only very rare cases 
of mature B cell ALL ( Burkitt leukemia) and T-cell 
ALL. 
Epidemiology 
Trisomy 21 has an incidence of approximately 1 in 
700 live births.  The frequency of acute 
lymphoblastic leukemia in Down syndrome (ALL-
DS) is estimated at 1 in 300 (Lange, 2000).  The 
incidence of ALL-DS <5 years of age is 40.7 times 
greater than that in individuals without Down 
syndrome of the same age; in addition, there remains 
an increased risk of ALL-DS compared to  those 
without Down syndrome up to the age of 30 years 
(Hasle et al., 2000).  However, unlike those without 
Down syndrome, ALL -DS usually does not present 
in patients <1 year of age. 
Clinics 
Other than the lack of presentation in children <1 
year of age, ALL-DS has similar clinical features to 
ALL in children without Down syndrome, including 
age, sex, presenting white blood cell count, and NCI 
risk group (Maloney et al., 2010).  Some studies 
identify similar rates of mediastinal masses and 
central nervous system involvement at diagnosis in 
those with ALL-DS and those with ALL without 
Down syndrome, but other studies identified 
decreased CNS disease and mediastinal masses in 
those with ALL-DS (Maloney, 2011). 
Cytology 
Blasts are characterized as small to medium in size 
with high nuclear-to-cytoplasmic ratios, round to 
irregular nuclei, smooth chromatin, and scant deeply 
basophilic agranular cytoplasm. 
Pathology 
The blasts of ALL-DS usually have an immature B 
cell phenotype, expressing CD19, CD10, and 
CD79a. 
Cytogenetics 
The cytogenetics of ALL-DS differs from the 
cytogenetics in those with ALL not associated with 
Down syndrome.  The children with ALL-DS have a 
Acute lymphoblastic leukemia in Down 
syndrome 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(8) 342 
 
decreased frequency of favorable cytogenetics 
including high hyperdiploidy, trisomies of 
chromosomes 4, 10, and 17, and the t(12;21) 
translocation compared to children without Down 
syndrome (Maloney et al., 2010; Bruwier and 
Chantrain, 2012); these ALL-DS children also have 
a decreased frequency of unfavorable translocations 
such as t(9;22) and 11q23 (MLL) rearrangements. 
Approximately 50-60% of ALL-DS have been found 
to have CRLF2 gene rearrangements by FISH or RT-
PCR (Mullighan et al., 2009; Hertzberg et al., 2010).  
The most common rearrangement is a deletion in the 
pseudoautosomal region 1 (PAR1) of Xp22.33/Yp11 
resulting in a fusion between the first noncoding 
exon on P2RY8 with the entire coding region of 
CRLF2 ( del(X)(p22.33p22.33)/del(Y)(p11p11)) 
(Mullighan et al., 2009). Less commonly, CRLF2 
rearrangements with IGH (immunoglobulin heavy 
chain locus) are identified 
(t(X;14)(p22;q32)/t(Y;14)(p11;q32)).  These fusions 
result in overexpression of CRLF2.  Overexpression 
of CRFL2 has not been found to be correlated with 
outcome. 
  
 
Figure 1:  Bone marrow aspirate smears reveal increased blasts which are small to medium in size with high 
nuclear-to-cytoplasmic ratios, round to irregular nuclei, smooth chromatin, and scant basophilic agranular 
cytoplasm.  Some background maturing myeloid cells are also present in this case. 
Overall, these common B-ALL gene rearrangements, which occur at a rate of approximately 60% in non-Down 
syndrome patients, only occur at a rate of approximately 20% in ALL-DS.  Instead, ALL-DS is more likely to 
have a normal karyotype (with the exception of the constitutional trisomy 21).  In those without normal 
karyotypes, DS-ALL are more likely to be low hyperdiploid, with common acquired changes including +X 
and/or del(9p) (Forestier et al., 2008; Lundin et al., 2014).  
 
 
Genes 
JAK2 activating mutations have been found in 
approximately 20% of ALL-DS, with the most 
common mutations occurring at or around amino 
acid R683 in the pseudokinase domain (Bercovich et 
al., 2008; Kearney et al., 2009; Gaikwad et al., 
2009); however, other JAK2 mutations have been 
identified in ALL-DS, as have mutation in other JAK 
genes including JAK1 (Mullighan et al., 2009).  
These JAK2 mutations are found predominantly in 
those with CRLF2 gene rearrangements.  JAK2 
mutation status has not been found to correlate with 
outcome.  The JAK2 mutations are thought to act in 
concert with the CRFL2 gene rearrangements, 
resulting in cytokine-independent growth and 
leukemogenesis (Mullighan et al., 2009).  
 
In addition to mutations in the JAK-STAT pathway, 
mutations in the RAS/receptor tyrosine kinase 
(RTK) pathway genes such as KRAS and NRAS 
have been identified at a rate of approximately 35%; 
these mutations are mutually exclusive of the JAK2 
mutations (Nikolaev et al., 2014).  However, similar 
to the JAK2 mutations, the RAS pathway mutations 
often occur in the setting of CRLF2 rearrangements.  
Nikolaev et al. (2014) also identified mutations in 
cohesion complex genes, epigenetic 
modifiers/remodellers of DNA or chromatin, 
classical tumor suppressor genes, and lymphoid 
Acute lymphoblastic leukemia in Down 
syndrome 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(8) 343 
 
differentiation factors/markers.  
 
Activating mutations in CRLF2 can also occur, again 
usually in the setting of CRLF2 gene rearrangements 
(Hertzberg et al., 2010).  
 
Deletions in IKZF1 are also often found in DS-ALL, 
estimated at 24-35% (Hertzberg et al., 2010; 
Buitenkamp et al., 2012), as are deletions in the 
PAX5 gene (12-22%) (Kearney et al., 2009; Lundin 
et al., 2012; Buitenkamp et al., 2012).  Patients with 
an IKZF1 deletion or a PAX5 deletion have 
decreased overall survival compared to those 
without these deletions (Buitenkamp et al., 2012). 
Treatment 
ALL-DS is treated similarly to ALL in those without 
Down syndrome.  However, some additional 
modifications and supportive care guidelines are 
often employed in their treatment, including the use 
of discontinuous dexamethasone during delayed 
intensification and adding leucovorin rescue after 
intrathecal methotrexate (Maloney, 2011).  Down 
syndrome patients have increased susceptibility to 
methotrexate, with higher rates of mucositis, 
gastrointestinal toxicity, and hepatotoxicity.  Some 
trials have decreased the methotrexate dosage, 
increasing the dose only if tolerated.  Additionally, 
Down syndrome patient have a higher risk of 
hyperglycemia after corticosteroids and 
asparaginase therapy due to alterations in glucose 
metabolism. 
Prognosis 
In some studies, children with ALL-DS have been 
found to have poorer outcomes than children with 
ALL without Down syndrome, sometimes 
demonstrating increased induction failures, higher 
relapse rates, and increased therapy-related 
mortality.  The poorer outcomes are thought to be 
due, at least in part, to increased sensitivity to 
methotrexate side effects, and increased 
susceptibility to infection.  The latter susceptibilities 
are thought to be enhanced by the inherent 
immunodeficiencies of Down syndrome.  However, 
more recently, with appropriate prognostic group 
identification based upon favorable and unfavorable 
cytogenetic features, ALL-DS has been found to 
have comparable outcomes to ALL not associated 
with Down syndrome (Maloney et al., 2010; 
Maloney, 2011).  In addition, Buitenkamp et al., 
2014 found favorable prognostic factors to include 
diagnosis < 6 years of age and a WBC 9/L.  
 
In those who relapse, ALL-DS has a lower event-free 
survival and lower overall survival compared to 
those with ALL without Down syndrome, usually 
due to induction deaths and treatment-related 
mortality (Meyr et al., 2013).  These relapses usually 
occur late (more than 6 months after completion of 
therapy) (Meyr et al., 2013; Buitenkamp et al., 
2014).  
 
In those who undergo a hematopoietic cell transplant 
(HCT), post-transplant relapse often occurs, with a 
probability of 54% within 3 years in one cohort, with 
an overall survival at 3 years of 29% (Hitzler et al., 
2014). 
Genes involved and 
proteins 
JAK2 (janus kinase 2) 
Location 
9p24.1 
Protein 
Protein tyrosine kinase involved in cytokine receptor 
signaling pathways. 
Somatic mutations 
Mutations often occur in the pseudokinase domain at 
or around R683 in exon 16 and result in constitutive 
kinase activity. 
IKZF1 (Ikaros family zinc finger 1) 
Location 
7p12.2 
Protein 
Zinc-finger DNA-binding protein that is a 
transcription factor associated with chromatin 
remodeling.  It is a transcription regulator of 
lymphocyte differentiation. 
Somatic mutations 
Usually deletions. 
PAX5 (paired box gene 5) 
Location 
9p13.2 
Protein 
Paired box transcription factor which has a role in B-
cell differentiation, involving regulation of CD19. 
Somatic mutations 
Usually deletions. 
KRAS (Kirsten rat sarcoma 2 viral 
oncogene homolog) 
Location 
12p12.1 
Protein 
RAS oncogene that is a member of the small GTPase 
family. 
NRAS (neuroblastoma RAS viral 
oncogene homolog) 
Location 
1p13.2 
Protein 
RAS oncogene that is a member of the small GTPase 
family. 
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CRLF2 (cytokine receptor-like factor 
2) 
Location 
Xp22.33 
Protein 
Encodes cytokine receptor-like factor 2 which is a 
lymphoid signaling receptor that dimerizes with 
interleukin-7 receptor ( IL7R) to form a receptor for 
thymic stromal lymphopoietin ( TSLP). This 
complex (CRLF2/IL7R/TSLP) can stimulate cell 
proliferation through activation of STAT3 and 
STAT5. 
Somatic mutations 
Most commonly, translocations occur with P2RY8 
or IGH.  In addition to the translocations, in some 
patients activating mutations in CRLF2 can also 
occur. 
P2RY8 (purinergic receptor P2Y, G-
protein coupled, 8) 
Location 
Xp22.33 
Protein 
Encodes a G-protein coupled purinergic receptor 
(P2Y, G-protein coupled, 8). 
Somatic mutations 
Through an interstitial deletion, the first noncoding 
exon of this gene hybridizes with the coding region 
of CRLF2. 
IGH (Immunoglobulin Heavy) 
Location 
14q32.33 
Protein 
Immunoglobulin heavy chain. 
Somatic mutations 
Through a translocation, this gene hybridizes to 
CRLF2. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
The P2RY8/CRLF2 fusion is much more common 
than the IGH/CRLF2 fusion. 
Description 
An interstitial deletion in the pseudoautosomal 
region 1 (PAR1) of Xp22.3/Yp11 occurs in the 
P2RY8/CRLF2 fusion, hybridizing the first 
noncoding exon of P2RY8 to the entire coding 
region of CRLF2 
[del(X)(p22.33p22.33)/del(Y)(p11.32p11.32)].  
Alternatively, a translocation occurs between 
CRLF2 and IGH resulting in 
t(X;14)(p22;q32)/t(Y;14)(p11;q32). 
Detection 
These fusions can be detected by FISH or RT-PCR. 
Fusion protein 
Oncogenesis 
Results in overexpression/dysregulated expression 
of CRLF2. 
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